This Article Full Text Full Text (PDF) All Versions of this Article: 37/8/2174    most recent 01.STR.0000231647.41578.dfv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chrissobolis, S. Articles by Sobey, C. G. Search for Related Content PubMed PubMed Citation Articles by Chrissobolis, S. Articles by Sobey, C. G. Pubmed/NCBI databases Domain Related Collections Cerebrovascular disease/stroke Other diabetes Endothelium/vascular type/nitric oxide Other Vascular biology Brain Circulation and Metabolism

(Stroke. 2006;37:2174.)
© 2006 American Heart Association, Inc.

Comments, Opinions, and Reviews

Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease

From the Department of Internal Medicine (S.C.), University of Iowa, Iowa City, and the Department of Pharmacology and Centre for Vascular Health Initiative (C.G.S.), Monash University, Clayton, Australia.

Correspondence to Christopher G. Sobey, PhD, Department of Pharmacology, Monash University, Wellington Road, Clayton, Victoria 3800, Australia. E-mail chris.sobey{at}med.monash.edu.au

Background and Purpose— The small G protein rhoA and its downstream effector rho-kinase are both expressed in vascular cells and are involved in several cellular processes. One of these processes is the regulation of the phosphorylation state of myosin light chain in vascular muscle and thus, the development of force. Recently, considerable evidence for increased activity of this pathway in cerebral and noncerebral vessels has been reported in several cardiovascular diseases associated with increased vascular tone.

Summary of Review— The main aim of this brief review is to summarize current evidence for the involvement of rhoA/rho-kinase signaling in dysfunction of the cerebral circulation in disease states, such as cerebral vasospasm, hypertension, diabetes, and ischemic brain injury. We will also briefly consider the novel hypothesis that augmented activity of endothelial rho-kinase decreases nitric oxide production and contributes to increased vascular tone in disease and the possibility of this action being a key therapeutic target of statins (inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase) in cerebral and noncerebral arteries.

Conclusions— Considerable evidence indicates that rhoA/rho-kinase activity is commonly increased in cerebral vascular disease, not only in vascular muscle, but also in the endothelium and possibly in inflammatory cells and neurons.

Key Words: cerebral arteries • cerebrovascular disorders • endothelium • muscle, smooth • phospholipids • statins

This article has been cited by other articles:

				B. Fibbi, A. Morelli, M. Marini, X.-H. Zhang, R. Mancina, L. Vignozzi, S. Filippi, A. Chavalmane, E. Silvestrini, E. Colli, et al. Atorvastatin But Not Elocalcitol Increases Sildenafil Responsiveness in Spontaneously Hypertensive Rats by Regulating the RhoA/ROCK Pathway J Androl, January 1, 2008; 29(1): 70 - 84. [Abstract] [Full Text] [PDF]

				K. A. Brown, S. P. Didion, J. J. Andresen, and F. M. Faraci Effect of Aging, MnSOD Deficiency, and Genetic Background on Endothelial Function: Evidence for MnSOD Haploinsufficiency Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1941 - 1946. [Abstract] [Full Text] [PDF]

				S. P. Didion, C. M. Lynch, and F. M. Faraci Cerebral vascular dysfunction in TallyHo mice: a new model of Type II diabetes Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1579 - H1583. [Abstract] [Full Text] [PDF]